RxDoctor Payments Data

Sushil Basra, MD

Orthopaedic Surgery of the Spine · Commack, NYNPI 1295948115

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $44,900 of the $53,662 with a category attached, or 83.7%. Royal Biologics, Inc. accounts for 83.9% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $20,951, more than ten times the $742 reported in 2019.

$53,662in general payments, 2019–2025

Across 231 payments — averaging $232.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Royal Biologics, Inc.$45K
  • Globus Medical$7K
  • Medtronic$449
  • DJO, LLC$264
  • Johnson & Johnson$147
  • Zimmer Biomet$107
  • plus $329 from 10 others

What the payments were for

  • Consulting fees$44,90084%
  • Travel & lodging$2,2044%
  • Food & beverage$6,55712%
  • Entertainment$00%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$53,662 in reported general payments places this provider in the 70th percentile of 161 orthopaedic surgery of the spine providers in New York.

See all orthopaedic surgery of the spine providers in New York

Medicare billing

Part B allowed, 2024
$161,985
Medicare patients
275
Services billed
925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cyclobenzaprine Hcl29$189
Gabapentin25$135
Methylprednisolone18$97

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery of the spine in Commack

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →